Expression Of Matrix Metalloproteinase-7 And Vascular Endothelial Growth Factor In Endometrial Cancer Tissues And Clinical Significance

Endometrial cancer, also known as uterine cancer, is a common gynecological cancer; the incidence rate is second only to cervical cancer. In Western countries the incidence rate in the female genital cancer first, and according to its incidence shows a clear upward trend. China in recent years the incidence of endometrial cancer has a clear upward trend. Endometrial cancer occurs in menopausal and post-menopausal women, more common in unmarried, less production, obesity and hypertension, diabetes, women. Is associated with polycystic ovarian syndrome, dysfunctional uterine bleeding, uterine fibroids and secretion of estrogen ovarian tumor, etc.Endoscopic endometrial cancer can be divided into Aden carcinoma, glandular cancer, kurtosis, squamous carcinoma, and clear cell carcinoma. Because of its hidden history, anatomical location of the deep, rapid development, so early diagnosis difficult, surgery is low, the prognosis is poor. Endometrial cancer has the real reason of disease of unknown, a number of studies have suggested that, endometrial cancer occurrence, and development is the result of many factors. In recent years, with the rapid development of molecular biology, endometrial cancer is a multi-gene-related diseases, the view gradually been accepted by the majority of scholars. For this study, by immunohistochemical staining to detect matrix metalloproteinase -7 (MMP-7) and vascular endothelial growth factor (VEGF) in endometrial cancer and adjacent tissues situation of MMP-7, VEGF and endometrial cancer, tumor size, lymph node metastasis and other pathological parameters of the relationship between, to analyze MMP-7 and VEGF in endometrial carcinoma and its relevance, and provide a theoretical basis for clinical treatment.Objective: To study the human endometrial cancer tissues MMP-7 and VEGF expression in endometrial carcinoma and its role in the development and clinical pathological features.Methods: 30 cases of endometrial cancer tissue specimens and corresponding adjacent tissues, using immunohistochemical methods (POLINK-2 two-step) detection of MMP-7, VEGF expression and clinical pathological features, and then analyze the MMP- 7, VEGF and tumor size, lymph node relationship. Results: 70% to 80% in patients with endometrial cancer have cancer MMP-7 and VEGF over expression. With endometrial carcinoma from small to large solid tumors, MMP-7 and VEGF positive expression rate gradually increased. In less than 2 cm, 2 ~ 4 cm and greater than 4 cm tumors, MMP-7 positive rates were 50%, 100% and 90% in the expression of MMP-7 and VEGF-positive patients with endometrial cancer lymph node metastasis was significantly higher than MMP-7 alone or the expression of VEGF-positive cases. In 30 cases of endometrial carcinoma, MMP-7 expression was 80%, while the expression of VEGF-positive rate was 70%, a correlation coefficient of 0.654, reflect the correlation between the two.Conclusion: Endometrial cancer in MMP-7 and VEGF were highly expressed MMP-7 and VEGF expression and tumor size, lymph node metastasis. Tip MMP-7 and VEGF protein to participate in the occurrence of endometrial cancer development and metastasis. Clinical testing the expression can be regarded as a judge malignant endometrial cancer biology behavior reference index.